about
Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities. Background Document to the ESHG recommendations on genetic testing and common disordersPhylogeography of Y-chromosome haplogroup I reveals distinct domains of prehistoric gene flow in europeAssessing the impact of biobanksInternational network of cancer genome projects.Prepublication data sharingOpen data sharing in the context of bioresourcesA human genome diversity cell line panelBiobankers: Treat the Poison of Invisibility with CoBRA, a Systematic Way of Citing Bioresources in Journal ArticlesDeveloping a guideline to standardize the citation of bioresources in journal articles (CoBRA)Practical guidelines addressing ethical issues pertaining to the curation of human locus-specific variation databases (LSDBs)Mechanisms of the Development of Allergy (MeDALL): Introducing novel concepts in allergy phenotypes.Whole-genome sequencing in health care. Recommendations of the European Society of Human Genetics.Whole-genome sequencing in health care: recommendations of the European Society of Human Genetics.Systems medicine and integrated care to combat chronic noncommunicable diseases.An empirical survey on biobanking of human genetic material and data in six EU countries.Handling missing values in population data: consequences for maximum likelihood estimation of haplotype frequencies.Introduction to statistical analysis of population data in immunogenetics.Linkage disequilibrium organization of the human KIR superlocus: implications for KIR data analysesResearch priorities. ELSI 2.0 for genomics and society.Beyond public health genomics: proposals from an international working group.Biobanking for Europe.Association analysis in type 1 diabetes of the PRSS16 gene encoding a thymus-specific serine protease.Tracing biological collections: between books and clinical trials.Genome Editing and Dialogic Responsibility: "What's in a Name?".A new classification of HLA-DRB1 alleles differentiates predisposing and protective alleles for autoantibody production in rheumatoid arthritisGenetic markers as a predictive tool based on statistics in medical practice: ethical considerations through the analysis of the use of HLA-B(*)27 in rheumatology in France.Strategies in analysis of the genetic component of multifactorial diseases; biostatistical aspects.A new classification of HLA-DRB1 alleles based on acid-base properties of the amino acids located at positions 13, 70 and 71: impact on ACPA status or structural progression, and meta-analysis on 1235 patients with rheumatoid from two cohorts (ESPOIDeveloping a policy for paediatric biobanks: principles for good practice.New classification of HLA-DRB1 alleles in rheumatoid arthritis susceptibility: a combined analysis of worldwide samples.Towards a European consensus for reporting incidental findings during clinical NGS testing.Biobanks for genomics and genomics for biobanks.Quantifying the use of bioresources for promoting their sharing in scientific researchMapping the translational science policy 'valley of death'Understanding the complexity of IgE-related phenotypes from childhood to young adulthood: a Mechanisms of the Development of Allergy (MeDALL) seminar.Systems medicine approaches for the definition of complex phenotypes in chronic diseases and ageing. From concept to implementation and policies.Measuring the contribution of tumor biobanks to research in oncology: surrogate indicators and bibliographic output.Italian appeal court: a genetic predisposition to commit murder?The social and ethical issues of post-genomic human biobanks.How to responsibly acknowledge research work in the era of big data and biobanks: ethical aspects of the Bioresource Research Impact Factor (BRIF).
P50
Q22330767-5ED18121-5A3A-4CE7-9CEB-E4437F945442Q24533494-C6354C3F-292E-440C-A06A-CC82979B293DQ24550681-BB5C574E-47A0-4100-852B-D7384527E960Q24611474-431E7CF3-277C-4AE4-B0C1-57DD8D0B6AD5Q26283296-1420538E-D37B-4363-8511-9ADC8163E4F7Q27009057-FFF63AC0-FF8F-45D8-8250-6DDD6E4F453AQ28214742-155A9A0B-7A36-4386-B431-197A39738839Q28597669-65EC109E-BA4B-44BA-BD94-1EF7DDC25CF7Q28649807-1D63A847-F10D-475B-871E-EAE7A76F66BFQ28744635-40A20421-3621-4360-BACB-6E9D0183CDA5Q30238498-28BC0131-916E-4C84-AFF3-6D0F759053C7Q30391597-F38DC4F3-8EE6-42D0-84BE-0A4C45D1A5BBQ30391601-CEBDE197-157D-4CFD-AD50-443851180979Q30395763-C38DC9CD-DAB7-4F4D-AC8E-D08D65D5FE37Q30798402-52E25C9C-C321-4FBF-AAE5-E93F1D0F7E90Q30943709-F46C3718-84D0-4FB6-AF47-B40A1F19B58AQ30993054-5F441EAF-085E-43A1-ABBC-DEA8F5E3ABE8Q33705522-65BA5EFC-31CC-487E-89F3-BA66BF49C27CQ34117892-3BDAEC43-FFF4-413B-ABB5-380D2948ADDDQ34435782-25C63884-CAB3-4A44-8E44-4BFDE5C300F6Q34584168-15568724-5EF7-4094-83ED-716AE41A5B64Q34640397-50DEE513-1271-49A6-B617-93D988A2FF14Q34780027-AF48574B-2763-4F44-9472-E0E91A97148EQ35859711-8EC6E062-B513-46BC-8442-F9C3C723E68CQ35868959-5ADF91A6-FE52-41CD-9F48-25F53E75A5CEQ36167880-529F3E96-5D21-4041-911A-8DB2236865E3Q36176653-99C6B150-2479-4EE0-A420-290DCC73F208Q36302259-294CAF6E-4627-457E-8AE1-20A5946F34C4Q36497109-6D04168D-1B44-4AF1-9254-DDE962A6F71FQ36641590-F5FF08DC-4DEC-4EDA-BE2B-78D42318A292Q36695676-55024746-B8FA-4194-98B3-DAD61F74B84DQ36748457-18DB94EC-E351-4E90-8409-4FD025D33537Q36847272-12564321-89DC-42D6-9657-3E86DC790278Q37060264-6BA74CD7-BEA7-4E89-ADA3-432153E732F2Q37990222-0637ED6A-9CDA-4174-95FA-9DFC6C38ACC6Q38196904-9FCFC454-F214-4E9D-8302-C7C342ECCF6FQ38213220-E4809687-1ED0-49CA-AB2D-F4FE2D978810Q41736602-2CC42D50-93F8-4CD0-A7E3-21B9765603D1Q42639498-AA79EB27-A2EB-45C8-B28F-33A1D0851A8CQ42693189-AD341C49-0FE5-415F-A359-518534636DEA
P50
description
onderzoeker
@nl
name
Anne Cambon-Thomsen
@ast
Anne Cambon-Thomsen
@en
Anne Cambon-Thomsen
@es
Anne Cambon-Thomsen
@nl
type
label
Anne Cambon-Thomsen
@ast
Anne Cambon-Thomsen
@en
Anne Cambon-Thomsen
@es
Anne Cambon-Thomsen
@nl
prefLabel
Anne Cambon-Thomsen
@ast
Anne Cambon-Thomsen
@en
Anne Cambon-Thomsen
@es
Anne Cambon-Thomsen
@nl